18F-FDG PET/CT for assessing therapeutic response to chemotherapy in patients with diffuse large B-cell lymphoma

VernacularTitle:18F-FDG PET/CT评价弥漫性大B细胞淋巴瘤化疗中期的治疗反应
Author: Hong-sheng, LI ; Hu-bing, WU ; Quan-shi, WANG ; Qiao-yu, WANG ; Bao-yuan, LI
Publication Type:Journal Article
Keywords: Lymphoma,large B-cell,diffuse; Drug therapy; Tomography,emission-computed; Tomography,X-ray computed; Deoxyglucose
From:Chinese Journal of Nuclear Medicine 2011;31(3):145-150
CountryChina
Language:Chinese
Abstract: Objective To explore the value of 18F-FDG PET/CT on the assessment of chemotherapy response in patients with diffuse large B-cell lymphoma (DLBCL). Methods 18F-FDG PET/CT was performed before and after 4 cycles of chemotherapy( R-CHOP or CHOP protocol) in 53 patients with DLBCL. The patients were divided into 3 groups: complete response group, partial response group and no response group. The therapeutic response was assessed by comparing post-treatment 18F-FDG PET/CT with pre-treatment PET/CT. Complete remission (CR) rate at the end of chemotherapy was calculated. χ2 test was performed with software SPSS 13.0. Results CR rates of complete response group, partially response group and no response group were 88.5% (23/26), 73.3% (11/15) and 8.3% (1/12), respectively (χ2=23.548, P=0.000). CR rates of the complete and partially response groups were significantly higher than those of no response group (χ2=22.656, P=0.000; χ2=11.407, P=0.001). Conclusion 18F-FDG PET/CT may be useful for the assessment of chemotherapy response in DLBCL.